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1ABSTRACT
Association between vitamin D deficiency and anemia in patients with 
end-stage renal disease
Yung Ly Kim
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Shin-Wook Kang)
Background Despite new treatment strategies, anemia remains the most 
prevalent complication in patients with end-stage renal disease. We investigated 
whether 25-hydroxyvitamin D deficiency is associated with anemia in end-stage 
renal disease patients.
Methods We reviewed the medical records of 410 end-stage renal disease
patients who had undergone renal transplantation at Yonsei University Health 
System, who had 25-hydroxyvitamin D levels measured at renal transplantation. 
Patients were divided into group 1 (25-hydroxyvitamin D levels < 10 ng/ml) 
and group 2 (25-hydroxyvitamin D levels ≥ 10 ng/ml). 
Results Multivariate linear regression analysis indicated an independent 
association between serum 25-hydroxyvitamin D and hemoglobin levels, after 
adjusting age, sex, logarithm (base 10) intact parathyroid hormone, phosphate, 
alkaline phosphatase, logarithm (base 10) high-sensitivity C-reactive protein, 
ferritin levels, and erythrocyte-stimulating agent dose (β = 0.035; p = 0.039). 
Odds ratio for developing anemia (hemoglobin level < 10 g/dl) showed that 
group 1 had a higher risk (Odds ratio = 3.283; confidence interval,
1.040–10.362; p = 0.043) for anemia than group 2, after adjusting for age, sex, 
log intact parathyroid hormone, phosphate, alkaline phosphatase, logarithm 
(base 10) high-sensitivity C-reactive protein, ferritin levels, and 
erythrocyte-stimulating agent use.
Conclusion 25-hydroxyvitamin D deficiency significantly associated with 
anemia in patients with end-stage renal disease patients. Randomized controlled 
trials are needed to determine if vitamin D supplementation can improve anemia 
in these patients.
------------------------------------------------------------------------------------------------
Key words: vitamin D deficiency; 25-hydroxyvitamin D; anemia; end-stage 
renal disease; chronic kidney disease
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I. INTRODUCTION
Anemia is a common finding in patients with chronic kidney disease (CKD), 
and its prevalence and severity are known to increase as renal function 
decreases. In addition, anemia is closely associated with a wide range of clinical 
symptoms and signs, resulting in poor quality of life and increased risk of 
morbidity and mortality in these patients.1 Recently, accumulating evidence 
indicates that vitamin D has pleiotropic effects in various organ systems based 
on the distribution of vitamin D receptors in the whole body.2 In addition to its 
well-known effect on bone and mineral metabolism, vitamin D has been 
revealed to play a protective role in a number of chronic diseases, including 
CKD-associated anemia.3 In fact, previous studies using the data of the Study to 
Evaluate Early Kidney Disease (SEEK) and the Third National Health and 
Nutrition Examination Survey (NHANES III) showed that vitamin deficiency 
was significantly and independently associated with anemia in patients with 
CKD not requiring dialysis.4,5 However, the relationship between serum 
25-hydroxyvitamin D [25(OH)D3] and hemoglobin (Hb) concentrations has not 
been extensively explored in patients with end-stage renal disease (ESRD). In 
this study, we attempted to elucidate the correlation of 25(OH)D3 with anemia 
in relatively healthy patients with ESRD who were admitted to the hospital for 
renal transplantation (RTx). Moreover, the independent impact of 25(OH)D3 on 
3anemia was clarified in these patients.
II. MATERIALS AND METHODS
Study population
We reviewed the medical records of 423 patients with ESRD who had 
undergone RTx at Yonsei University Health System in Seoul, Korea (latitude: 
37.5°N; average annual sunshine: 5.8 hours per day) between April 2002 and 
December 2008 and whose 25(OH)D3 levels were measured at the time of RTx.
Among these patients, 13 were excluded for being aged < 18 years (n = 6) or >
70 years (n = 7). Thus, the final analysis involved 410 RTx patients. All 
participants were from an ethnically homogeneous Korean population.
Data collection
Although 1,25-dihydroxyvitamin D is the active form of vitamin D, its 
half-life is only 4–6 hrs in the circulation. In the clinical field, therefore, 
25(OH)D3 is regarded as the best index to assess vitamin D status because of its 
long half-life of approximately 3 weeks.6 The serum 25(OH)D3 concentrations 
were determined at the time of RTx by a radioimmunoassay method using the 
25-HYDROXYVITAMIN D 125I RIA KIT (68100E) (DiaSorin Inc., Stillwater, 
MN, USA).7 According to the opinion of most experts, vitamin D deficiency is 
defined as serum 25(OH)D3 levels < 10 ng/ml (25 nmol/l), vitamin D 
insufficiency as 25(OH)D3 levels 10–29 ng/ml (25–72 nmol/l), and vitamin D 
sufficiency as 25(OH)D3 levels ≥ 30 ng/ml (73 nmol/l).6, 8-13 Since there were
no patients with vitamin D sufficiency, the patients were divided into two 
groups for analysis: group 1, 25(OH)D3 < 10 ng/ml and group 2, 25(OH)D3 ≥
10 ng/ml. Demographic and clinical data at the time of RTx, including age, sex, 
dialysis modality before RTx, duration of dialysis, comorbidities, season at the 
time of RTx, and erythrocyte-stimulating agent (ESA) dose, were recorded. To 
further study the association between 25(OH)D3 levels and ESA requirements, 
4the ESA dose/Hb index was calculated by dividing the monthly ESA dose 
(units) by Hb concentration. The results of the following biochemical laboratory 
tests were also collected: Hb, intact parathyroid hormone (iPTH), serum iron, 
total iron-binding capacity (TIBC), transferrin saturation (TSAT), ferritin, 
alkaline phosphatase (ALP), serum phosphate, calcium, albumin, estimated 
glomerular filtration rate (eGFR), and high-sensitivity C-reactive protein 
(hs-CRP) levels.
Statistical analysis
Statistical analysis was performed using SPSS version 20.0 (SPSS Inc., 
Chicago, IL, USA). Continuous variables were expressed as mean ± standard 
deviation or median ± interquartile range for skewed data. The 
Kolmogorov-Smirnov test was used to analyze the normality of the distribution 
of measured parameters, and categorical variables were presented as a number 
(percentage). The patients were divided into two groups based on serum 
25(OH)D3 concentrations (< 10 ng/ml and ≥ 10 ng/ml). The differences 
between the two groups were determined by the Student’s t test or 
Mann-Whitney U test for continuous variables and the X2-method for
categorical variables. The relationship between Hb and 25(OH)D3 levels was 
assessed using Pearson’s correlation analysis. The independent association 
between 25(OH)D3 and Hb levels was evaluated using a multivariate linear 
regression analysis. A logistic regression analysis was used to estimate odds 
ratios (ORs) and to identify independent risk factors for anemia. The National 
Kidney Foundation-Kidney Disease Outcomes Quality Initiative 
(NKF-KDOQI) guidelines (2012) recommended that Hb targets should be in the 
range of 10.0–11.5 g/dl, regardless of whether the patients were receiving 
dialysis.13 Therefore, we defined anemia as a Hb level < 10 g/dl. In all cases, a
p-value < 0.05 was considered statistically significant.
5III. RESULTS
Baseline characteristics
Among a total of 410 patients who had undergone RTx, 171 (41.7%) were 
vitamin D deficient, 239 (58.7%) were vitamin D insufficient, and no patients 
had normal serum 25(OH)D3 concentrations. Since no patients had normal 
vitamin D levels, the patients were divided into only two groups: patients with 
vitamin D deficiency (group 1) or without vitamin D deficiency (group 2).
Demographic, clinical, and biochemical data are shown in Table 1. The mean 
age was 40.7 ± 11.4 years, and 262 patients (63.9%) were male. The mean
serum 25(OH)D3 concentration was 11.1 ± 6.4 ng/ml, while the mean 
25(OH)D3 level was 6.5 ± 1.8 ng/ml in group 1 and 17.2 ± 5.6 ng/ml in group 2. 
There were no differences in age, dialysis modality, season at the time of RTx, 
and comorbidities between the two groups. However, the following factors were 
significantly different between the two groups. Group 2 had a higher proportion 
of men than group 1 (69.9%; p = 0.003). The proportion of patients who met the 
criteria for anemia (60.2%; p < 0.001) and ESA use (53.8%; p = 0.013) was 
significantly higher in group 1. Moreover, the monthly ESA dose was 
significantly higher in group 1 (20656.2 ± 17627.7; p = 0.003). As seen in Table 
1, serum phosphate, calcium, and albumin concentrations were significantly 
lower in group 1 than in group 2. In contrast, there were no significant 
differences in serum levels of iPTH, serum iron, TIBC, TSAT, ferritin, ALP,
eGFR, and hs-CRP.
6Table 1. Baseline clinical characteristics of patients according to 
25-hydroxyvitamin D levels
Variable Total Group 1
25(OH)D3
< 10 ng/ml
Group 2
25(OH)D3
≥ 10ng/ml
p-value
§
n (%) 410 171 (41.7%) 239 (58.7%)
Demographic data
Age (years) 40.7±11.4  40.8±10.5 41.3±11.3 0.662
Male sex, n (%) 262 (63.9%) 95 (55.5%) 167 (69.9%) 0.003
Anemia (Hb < 10g/dl) 175(42.7%) 103 (60.2%) 72 (30.1%) <0.001
Dialysis (%) 0.395
Hemodialysis 199 (48.5%) 58 (34.0%) 162 (68.8%)
Peritoneal dialysis 78 (19.0%) 22 (24.5%) 14 (6.3%)
No dialysis 133 (32.4%) 91 (53.2%) 63 (26.3%)
Duration of dialysis (mo) 20.4±37.3  16.8±33.1 23.3±40.5 0.236
Season of RTx 0.718
Spring 90 (22.0%) 51 (29.8%) 39 (16.3%)
Summer 107 (26.1%) 29 (17.0%) 78 (32.6%)
Autumn 101 (24.6%) 37 (21.6%) 64 (26.8%)
Winter 112 (27.3%) 54 (31.6%) 58 (24.3%)
Co-morbidities (%)
Diabetes 77(18.8%) 38 (22.2%) 39 (16.3%) 0.132
Hypertension 364 (88.8%) 155 (90.6%) 209 (87.4%) 0.313
Medications
Use of ESA 191 (46.5%) 92 (53.8%) 99 (41.4%) 0.013
ESA dose, units/mo 16956.5±17252.2 20656.2±17627.7 10970.7±16146.2 0.003
ESA dose/Hb index 1842.9±1935.3 2227.5±1929.9 1133.0±1718.4 0.001
Biochemical data
25(OH)D3 
(ng/ml)(median)
11.1±6.4 6.5±1.8 17.2±5.6 <0.001
Hb (g/dl) 9.9±1.9 9.7±2.0 10.5±1.6 <0.001
iPTH (pg/ml)(median) 168.3±164.9 152.3±220.7 225.2±243.0 0.677
Serum iron (ug/dl) 77.1±55.3 77.9±47.1 72.5±58.5 0.814
TIBC (µg/dl) 202.8±85.6 194.1±84.1 209.9±86.7 0.785
TSAT 38.0±86.4 33.3±21.8 41.3±11.6 0.357
Ferritin (ng/ml) 193.2±143.9 190.6±156.2 196.5±128.3 0.391
ALP (IU/l) 60.6±26.1 58.1±23.3 63.7±27.0 0.676
Phosphate (mg/dl) 5.3±1.4 5.0±1.4 5.7±1.3 0.001
Calcium (mg/dl) 7.7±1.0 7.4±0.9 8.1±1.0 0.001
Albumin (g/dl) 3.9±0.4 3.8±0.4 4.0±0.4 0.001
eGFR (ml/min/1.73 m²) 4.9±2.7 4.9±2.2 4.7±1.7 0.567
hs-CRP (mg/l)(median) 0.15±2.2 0.13±2.3 0.19±2.0 0.560
Patients had 25-hydroxyvitamin D levels measured at renal transplantation.
§P-value comparisons between group 1 and group 2.
7Results are expressed as x ± SD, median ± interquartile range or n (%) 
25(OH)D3, 25-hydroxyvitamin D; Hb, hemoglobin; RTx, renal transplantation; ESA, erythrocyte 
stimulating agent; iPTH, intact parathyroid hormone; TIBC, total iron binding capacity; TSAT, 
transferrin saturation; ALP, alkaline phosphatase; eGFR, estimated glomerular filtration rate; 
hs-CRP, high-sensitivity C-reactive protein
Correlation between vitamin D deficiency and anemia
Pearson’s correlation analysis revealed a significant correlation between 
25(OH)D3 and Hb levels (r = 0.292; p < 0.001). Hb level also significantly 
correlated with albumin (r = 0.267; p < 0.001) and calcium levels (r = 0.309; p
= 0.040). Pearson’s correlation analysis revealed a significant negative 
correlation between ESA dose/Hb index and 25(OH)D3 level (r = -0.176 p < 
0.001). ESA dose/Hb level also negatively correlated with Hb (r = -0.329; p < 
0.001), albumin (r = -0.172; p < 0.001), and calcium levels (r = -0.099; p = 
0.046). 
Effect of vitamin D deficiency on anemia
A multivariate linear regression analysis showed that serum 25(OH)D levels 
were independently associated with Hb levels after adjusting for age, sex, log 
iPTH, phosphate, ALP, logarithm (base 10) (log) hs-CRP, ferritin levels, and 
ESA dose (β = 0.035; p= 0.039) (Table 2). Similarly, serum 25(OH)D3 level 
was independently associated with the ESA dose/Hb index according to 
multivariable regression models (β = -0.590; p = 0.016) (Table 3). The ORs for 
developing anemia using a logistic regression analysis showed that group 1 
patients had a higher risk (OR, 3.283; 95% confidence interval [CI], 
1.040–10.362; p = 0.043) of developing anemia than group 2 patients after 
adjusting for age, sex, log iPTH, phosphate, ALP, log hs-CRP, ferritin levels, 
and ESA use (Table 4). 
8Table 2. Multivariate linear regression analysis with hemoglobin as the 
dependent variable
β p-value
25(OH)D3 0.035 0.039
Age 0.020 0.408
Sex (male/female) 0.202 0.677
Log iPTH -0.349 0.073
Phosphate -0.179 0.340
ALP -0.003 0.689
Log hs-CRP -0.192 0.283
Ferritin 0.002 0.120
ESA dose -0.001 0.031
25(OH)D3, 25-hydroxyvitamin D; Log, logarithm; iPTH, intact parathyroid hormone; ALP, 
alkaline phosphatase; hs-CRP, high-sensitivity C-reactive protein; ESA, erythrocyte stimulating 
agent
Table 3. Multivariate linear regression analysis with erythrocyte 
stimulating agent dose/hemoglobin index as the dependent variable
β p-value
25(OH)D3 -0.590 0.016
Age -0.342 0.345
Sex (male/female) -0.243 0.266
Log iPTH -0.401 0.073
Phosphate 0.712 0.130
ALP 0.301 0.628
Log hs-CRP 0.401 0.636
Ferritin 0.602 0.899
25(OH)D3, 25-hydroxyvitamin D; Log, logarithm; iPTH, intact parathyroid hormone; ALP, 
alkaline phosphatase; hs-CRP, high-sensitivity C-reactive protein
9Table 4. Odds ratio for developing anemia (hemoglobin < 10g/dl) using 
logistic regression analysis
Variable ORs (95% CI) p-value
25(OH)D3 < 10 vs ≥ 10 3.283 (1.040-10.362) 0.043
Age 
(per 1 year increase)
0.965 (0.918-1.015) 0.965
Sex (male vs female) 0.436 (0.127-1.495) 0.170
Log iPTH
(per 1 pg/ml increase)
1.322 (0.775-2.256) 0.520
Phosphate
(per 1 mg/dl increase)
0.874 (0.560-1.363) 0.552
ALP
(per 1 IU/l increase)
1.003 (0.981-1.026) 0.762
Log hs-CRP
(per 1 mg/l increase)
1.156 (0.743-1.799) 0.520
Ferritin
(per 1 ng/ml increase)
1.103 (0.993-1.033) 0.219
ESA use
(yes vs no)
2.960 (0.843-10.395) 0.090
ORs, Odds ratio; CI, confidence interval; 25(OH)D3, 25-hydroxyvitamin D; Log, logarithm; 
iPTH, intact parathyroid hormone; ALP. Alkaline phosphatase; hs-CRP, high-sensitivity 
C-reactive protein; ESA, erythrocyte stimulating agent
IV. DISCUSSION
Previous studies have demonstrated an association between serum vitamin D 
and Hb levels in patients with CKD who do not require dialysis5, 15; however, 
the impact of vitamin D deficiency on anemia has not been extensively explored 
in patients with ESRD. 
In this study, we demonstrated that patients with 25(OH)D3 levels < 10 ng/dl
had a higher risk of developing anemia than patients with 25(OH)D3 levels ≥ 10 
ng/dl. This association remained significant even after adjusting for potentially 
important risk factors for anemia. These findings are of great clinical 
significance, as anemia is very common in CKD patients and is associated with 
negative clinical outcomes.16-18 The National Kidney Foundation-Kidney 
Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines (2012) 
recommended 10g/dl as the lowest Hb level in CKD patients.14 Hb levels < 
10
10g/dl can increase the need for transfusion and the risks of cardiovascular 
complications and mortality in CKD patients.19, 20 Several factors have been 
identified as risk factors for anemia. Based on our data, we suggest that vitamin 
D deficiency, a modifiable condition, could be an additional risk factor for 
anemia in ESRD patients. 
Several potential mechanisms could explain the association between 
vitamin D deficiency and anemia in ESRD patients. Vitamin D was previously 
shown to directly stimulate erythroid precursor cells in CKD patients, and a
burst forming unit-erythroid (BFU-E) assay revealed that combined low doses 
of erythropoietin and vitamin D significantly increased the proliferation of 
mononuclear cells isolated from the peripheral blood of CKD patients compared 
to low-dose erythropoietin alone.21 Moreover, BFU-E proliferation was further 
potentiated by high-dose vitamin D,22 although this was not observed with cells 
isolated from healthy subjects. Taken together, these findings suggest that 
vitamin D has a direct effect on erythroid precursor proliferation in CKD 
patients but not in patients with normal renal function.
In addition, there is growing evidence that inflammatory cytokines influence 
erythropoiesis in CKD patients.23 Moreover, vitamin D deficiency was 
associated with secondary hyperparathyroidism, which is known to induce bone 
marrow fibrosis and suppress erythropoiesis in CKD patients.24 Taken together, 
these findings suggest that vitamin D has multiple effects on erythropoiesis in 
CKD patients, including the direct stimulation of erythropoietic cell 
proliferation, inhibition of inflammatory cytokines leading to increased iron 
availability, and a reduction in parathyroid hormone concentrations.
In this study, vitamin D deficiency was found to be an independent risk factor 
for anemia in patients with ESRD, which is in agreement with the results of 
most previous studies of patients with early CKD and patients undergoing
hemodialysis. Although no significant differences in serum hs-CRP and iPTH 
levels were found with respect to vitamin D deficiency, the concentration of 
11
both were lower in patients with vitamin D deficiency. Furthermore, Pearson’s 
correlation analysis revealed no relationships between Hb levels and serum 
hs-CRP, iPTH, or iron levels. Based on these findings, it seems likely that the 
weak association between inflammation, hyperparathyroidism, and iron profiles 
with anemia in the present study was a result of our patients being relatively 
healthy and stable with minimal inflammation, acceptably controlled secondary 
hyperparathyroidism, and a good nutritional status.
This study had several limitations. First, the number of patients was 
relatively small. Second, since the study subjects were all korean patients with 
ESRD, the associations of vitamin D with anemia and erythropoietin resistance 
may not be generalizable to other populations. Finally, serum vitamin D 
concentrations were measured only once at the time of RTx; therefore, it was 
difficult to conclusively determine whether the changes in serum vitamin D 
levels had any influence on the changes in Hb concentrations and erythropoietin 
resistance. 
V. CONCLUSION
In conclusion, vitamin D deficiency was prevalent in patients with ESRD 
undergoing RTx and was found to be independently associated with anemia and 
erythropoietin resistance. Further studies will be needed to verify the 
association of vitamin D deficiency with anemia and erythropoietin resistance 
through evaluating the effect of vitamin D replacement in patients with ESRD.
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ABSTRACT(IN KOREAN)
말기신부전 환자에서 비타민 D 결핍과 빈혈의 연관성
<지도교수 강신욱>
연세대학교 대학원 의학과
김 영 리
배경 말기 신부전 환자에서 빈혈의 다양한 치료법이 소개 되었음에도
불구하고 여전히 빈혈은 말기신부전 환자에서 가장 흔한 합병증으로
알려져 있다. 본 연구에서는 말기 신부전 환자에서 빈혈과 비타민 D 
(25-수산화비타민 D) 결핍과 연관되어 있는지 여부를 알아보고자
연구를 진행하였다. 
방법 신촌 세브란스 병원에서 신 이식술을 시행 받았던 410명의
환자를 대상으로 연구를 진행하였다. 이들의 신 이식술 당시
25-수산화 비타민 D 수치를 측정하였다. 이 수치에 따라 25-수산화
비타민 D 수치가 10 ng/ml 미만인 군을 그룹 1 으로, 10 ng/ml 이상인
군을 그룹 2 으로 나누어 분석하였다. 
결과 다변량 선형 회귀 분석법을 사용하여 분석하였을 때 혈청
25-수산화 비타민 D 수치는 혈색소 수치와 나이, 성별, 로그 완전한
부갑상선 호르몬, 인산염, 알칼리 인산분해효소, 로그 고감도
C-반응성 단백검사, 페리틴, 적혈구 생성 자극제 사용 여부를 보정
하였을때도 의미 있게 연관성이 있는 것으로 분석되었다 (p = 0.039). 
혈색소 10g/dl 미만의 빈혈이 발생할 오즈비는 나이, 성별, 로그
완전한 부갑상선 호르몬, 인산염, 알칼리 인산분해효소, 로그 고감도
C-반응성 단백검사, 페리틴, 적혈구 생성 자극제 사용 여부를 보정
하였을때도 그룹 1 에서 그룹 2 보다 높은 것을 확인 하였다 (p = 
0.039). 
결론 25-수산화 비타민 D 의 결핍은 말기신부전 환자에서 빈혈과
통계적으로 유의하게 연관성이 있음을 확인하였다. 이러한
환자군에서 비타민 D 투약이 빈혈을 호전 시켜줄지 여부에 대해서는
추후 추가적인 전향적인 연구가 필요하리라고 판단 된다.  
----------------------------------------------------------------------------------------
핵심되는 말: 비타민 D 결핍, 25-수산화 비타민 D, 빈혈, 말기신부전, 
만성신부전
